Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupDermatologic OncologyradiotherapyDiseaseMerkel Cell CarcinomaSubgroupSomatostatin receptor positiveICD10C44.9MeSHCarcinoma, Merkel CellSequenceCRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part A (PID109) -|- CRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part B (PID1111)ChemotherapyChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideNo. Substances1234567Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseneoadjuvantTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCardiotoxicityCholelithiasisColitisConstipationDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHyperbilirubinemiaHyperglycemiaHyperthyroidismHyponatremiaHypotensionHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMyocarditisNauseaNeutropeniaPancreatitisPneumonitisPruritusRashRenal FailureThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorAkaike TCancer Care OntarioKaufmann HKim SNghiem PPoulsen MTopalian SL DiseaseChemotherapierefraktäres Merkelzellkarzinomfortgeschrittenes MerkelzellkarzinomMerkellzellkarzinom, nicht operabelMerkelzellkarzinomMerkelzellkarzinom, ECOG 0-2Merkelzellkarzinom, resektabel, ECOG 0-1Merkelzellkarzinom, Stadium IV, nicht resektabel, rezidiviert, auch nach Therapie mit PD-1- oder PD-L1-InhibitorenOriginCancer Care Ontario, Drug Formulary, RegimenDepartment of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Medicine, University of Washington, Seattle, WA, USADivision of Cancer Services, Princess Alexandra Hospital,University of QueenslandDivision of Cancer Services, Princess Alexandra Hospital, University of QueenslandRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USASidney Kimmel Comprehensive Cancer Center, Baltimore, MD, CheckMate 358 studyUniversity of Washington Medical Center Protocols in Revision 13 protocols foundProtocols under revision.Avelumab 800, Merkel Cell Carcinoma (PID1076)Carboplatin 2 / Radiation followed by Carboplatin 4.5 / Etoposide 80, Merkel Cell Carcinoma Part B (PID1111)Carboplatin 2 / Radiation followed by Carboplatin 4.5, Etoposide 80, Merkel Cell Carcinoma Part A (PID109)Carboplatin 5 / Etoposide 100, Merkel Cell Carcinoma (PID1107)Cisplatin 25 / Etoposide 100, Merkel Cell Carcinoma (PID1108)Etoposide (50/100) / Paclitaxel 200 / Carboplatin 5, Merkel Cell Carcinoma (PID117)Etoposide 100, Merkel Cell Carcinoma (PID116)Etoposide 50, Merkel Cell Carcinoma (PID115)Nivolumab 240 / Ipilimumab 1, Merkel Cell Carcinoma (PID2414)Nivolumab 240, Merkel Cell Carcinoma, neoadjuvant (PID2413)Octreotide LAR 30, Merkel Cell Carcinoma (PID2415)Pembrolizumab 200, Merkel Cell Carcinoma, first-line (PID1285)Pembrolizumab 200, Merkel Cell Carcinoma, second-line (PID1078)